Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure
Open Access
- 28 March 2013
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 368 (13), 1210-1219
- https://doi.org/10.1056/nejmoa1214865
Abstract
Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia. In this randomized, double-blind trial, we assigned 2278 patients with systolic heart failure and mild-to-moderate anemia (hemoglobin level, 9.0 to 12.0 g per deciliter) to receive either darbepoetin alfa (to achieve a hemoglobin target of 13 g per deciliter) or placebo. The primary outcome was a composite of death from any cause or hospitalization for worsening heart failure. The primary outcome occurred in 576 of 1136 patients (50.7%) in the darbepoetin alfa group and 565 of 1142 patients (49.5%) in the placebo group (hazard ratio in the darbepoetin alfa group, 1.01; 95% confidence interval, 0.90 to 1.13; P=0.87). There was no significant between-group difference in any of the secondary outcomes. The neutral effect of darbepoetin alfa was consistent across all prespecified subgroups. Fatal or nonfatal stroke occurred in 42 patients (3.7%) in the darbepoetin alfa group and 31 patients (2.7%) in the placebo group (P=0.23). Thromboembolic adverse events were reported in 153 patients (13.5%) in the darbepoetin alfa group and 114 patients (10.0%) in the placebo group (P=0.01). Cancer-related adverse events were similar in the two study groups. Treatment with darbepoetin alfa did not improve clinical outcomes in patients with systolic heart failure and mild-to-moderate anemia. Our findings do not support the use of darbepoetin alfa in these patients. (Funded by Amgen; RED-HF ClinicalTrials.gov number, NCT00358215.)Keywords
This publication has 22 references indexed in Scilit:
- Pathophysiology of Anemia in Heart FailureHeart Failure Clinics, 2010
- Bone marrow dysfunction in chronic heart failure patientsEuropean Journal of Heart Failure, 2010
- Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and AnemiaCirculation, 2008
- The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMETEuropean Heart Journal, 2006
- Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart FailureCirculation, 2006
- Once-Monthly Administration of Darbepoetin Alfa for the Treatment of Patients with Chronic Heart Failure and AnemiaJournal of Cardiovascular Pharmacology, 2005
- Anemia in Patients With Heart Failure: Prevalence and Prognostic Role in a Controlled Trial and in Clinical PracticeJournal of Cardiac Failure, 2005
- Anemia and heart failureCurrent Heart Failure Reports, 2004
- Anemia and Its Relationship to Clinical Outcome in Heart FailureCirculation, 2004
- The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled studyJournal of the American College of Cardiology, 2001